MKGAF (Merck KGaA) Current Accrued Expense: $0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MKGAF Merck KGaA MKGAF
87 GF Score
Price $155.97
GF Value $161.93
Valuation Fairly Valued
! 10 Warning Signs
View Full Analysis

What is Merck KGaA Current Accrued Expense?

Merck KGaA MKGAF -0.88% 87 Current Accrued Expense is $0 Mil as of Jun. 2026. GuruFocus rates MKGAF with a GF Score™ of 87/100 and a GF Value™ of $161.93 (Fairly Valued). The stock has 10 warning signs investors should review.

Merck KGaA's Current Accrued Expense for the quarter that ended in Jun. 2026 was $0 Mil.

Merck KGaA's quarterly Current Accrued Expense declined from Dec. 2025 ($35 Mil) to Mar. 2026 ($0 Mil) but then stayed the same from Mar. 2026 ($0 Mil) to Jun. 2026 ($0 Mil).

Merck KGaA's annual Current Accrued Expense declined from Dec. 2023 ($888 Mil) to Dec. 2024 ($830 Mil) but then increased from Dec. 2024 ($830 Mil) to Dec. 2025 ($843 Mil).

Merck KGaA Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Merck KGaA's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Merck KGaA Current Accrued Expense Chart

Merck KGaA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,025.75 991.48 888.14 830.47 843.26

Merck KGaA Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 35.23 0.00 0.00
MKGAF
87GF Score
Merck KGaA MKGAF
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Merck KGaA Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $0 Mil mean?
Merck KGaA (MKGAF) has a Current Accrued Expense of $0 Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Merck KGaA and its competitors.
Is Merck KGaA's Current Accrued Expense too high?
Merck KGaA's current Current Accrued Expense is $0 Mil. Overall, Merck KGaA has a GF Score™ of 87/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Merck KGaA's Current Accrued Expense compare to ZTS and UTHR?
Merck KGaA's Current Accrued Expense of $0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Drug Manufacturers company?
A good Current Accrued Expense depends on the Drug Manufacturers industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Merck KGaA and its competitors. Merck KGaA's current Current Accrued Expense is $0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Merck KGaA stock overvalued right now?
Based on GuruFocus' analysis, Merck KGaA (MKGAF) is currently considered Fairly Valued. The stock's GF Value™ is $161.93, compared to a current price of $155.97 — trading 3.7% below its estimated fair value. The current Current Accrued Expense is $0 Mil. Merck KGaA's overall GF Score™ is 87/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Merck KGaA (MKGAF), the current Current Accrued Expense is $0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Merck KGaA (MKGAF) Overvalued in 2026?

Based on GuruFocus' analysis, Merck KGaA stock appears to be undervalued. The current stock price of $155.97 is trading 3.7% below its estimated GF Value™ of $161.93. GuruFocus considers Merck KGaA to be Fairly Valued.

Key valuation signals for MKGAF:

  • Current Accrued Expense: $0 Mil
  • GF Value™: $161.93 vs. price of $155.97 (3.7% below fair value)
  • GF Score™: 87/100 with 10 warning signs

No single metric tells the full story. See the MKGAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Merck KGaA Business Description

Address Frankfurter Strasse 250, Darmstadt, HE, DEU, 64293
Merck KGaA operates in three main segments: Life Science, Electronics, and Healthcare. The Life Science segment provides laboratory consumables and instruments to researchers in academia and applied fields, including the biopharmaceutical industry. The Electronics segment offers specialty materials to manufacture a variety of products, such as semiconductors and flat-screen televisions. In the healthcare segment, Merck develops, manufactures, and sells branded pharmaceuticals with significant therapeutic concentrations in oncology, multiple sclerosis, and fertility. In 1995, the E. Merck KG family publicly sold part of the company, resulting in the current 30% public ownership of the firm.
87GF Score

Get the complete analysis for MKGAF

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$155.97
Price
$161.93
GF Value